Drug makers leave the pain behind
Developing non-opioid analgesics remains one of the hardest tasks in biopharma.
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Late-stage pain pipeline refuses to swell
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
Neurocrine provides some good news in Huntington’s
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
